Bio: Barbara Pierce Bush

Bio: Barbara Pierce Bush

10:02 PM CST on Wednesday, March 4, 2009

The White House 2009

Rarely has a First Lady been greeted by the American people and the press with the approbation and warmth accorded to Barbara Pierce Bush. Perhaps this is prompted by the image she calls "everybody's grandmother." People are comfortable with her white hair, her warm, relaxed manner, and her keen wit. With characteristic directness, she says people like her because they know "I'm fair and I like children and I adore my husband."

AP

Barbara Bush

Barbara was born in 1925 to Pauline and Marvin Pierce, who later became president of McCall Corporation. In the suburban town of Rye, New York, she had a happy childhood. She went to boarding school at Ashley Hall in South Carolina, and it was at a dance during Christmas vacation when she was only 16 that she met George Bush, a senior at Phillips Academy in Andover, Massachusetts. They became engaged a year and a half later, just before he went off to war as a Navy torpedo bomber pilot. By the time George returned on leave, Barbara had dropped out of Smith College. Two weeks later, on January 6, 1945, they were married.

After the war, George graduated from Yale, and they set out for Texas to start their lives together. Six children were born to them: George, Robin, Jeb, Neil, Marvin, and Dorothy. Meanwhile, George built a business in the oil industry. With Texas as home base, he then turned to politics and public service, serving as a member of Congress, U. S. Ambassador to the United Nations, Chairman of the Republican National Committee, Chief of the U. S. Liaison Office in the People's Republic of China, Director of the Central Intelligence Agency, and later as Vice President. In those 44 years of marriage, Mrs. Bush managed 29 moves of the family.

When her husband was away, she became the family linchpin, providing everything from discipline to carpools. The death of their daughter Robin from leukemia when she was not quite four left George and Barbara Bush with a lifelong compassion. She says, "Because of Robin, George and I love every living human more."

Barbara Bush was always an asset to her husband during his campaigns for public office. Her friendly, forthright manner won her high marks from the voters and the press. As wife of the Vice President, she selected the promotion of literacy as her special cause. As First Lady, she called working for a more literate America the "most important issue we have." Involved with many organizations devoted to this cause, she became Honorary Chairman of the Barbara Bush Foundation for Family Literacy. A strong advocate of volunteerism, Mrs. Bush helped many causes—including the homeless, AIDS, the elderly, and school volunteer programs.

Today Barbara Bush lives in a home she and her husband built in Houston, Texas, where she enjoys being part of the community. Their children and grandchildren visit them often in Houston and at the family summer home in Kennebunkport, Maine. Devoted to her family, Mrs. Bush still finds time to work on an autobiography, serve on the Boards of AmeriCares and the Mayo Clinic, and continue her prominent role in the Barbara Bush Foundation.

Source:  The White House 2009

Bio-Tech Medical Software, Inc. Developing State-of-the-Art Anti-Drug Diversion Software in the UCF Technology Incubator

ORLANDO--(BUSINESS WIRE)--Bio-Tech Medical Software, Inc. is a leading developer of technology to eliminate prescription drug abuse. The Company announced today that it has been selected by the University of Central Florida's award winning Technology Incubator to become a part of the university's highly sophisticated and state-of-the-art incubator program. The University Incubator's Research Park Site Manager, Carol Ann Dykes, expressed, "We are very pleased to have Bio-Tech Medical Software, Inc. as a new client of the UCF's Incubation Program. We are excited and look forward to the opportunity to help them rapidly grow their business."

Under the terms of the agreement, Bio-Tech Medical Software, Inc., will utilize UCF's Incubation Program and the Company's elite technology in an effort to establish the most advanced prescription monitoring program for patients, physicians, and pharmacies. This system is aimed at stopping "doctor shoppers" from going to more than one doctor to obtain narcotic pain medication, thus allowing the legitimate patient to obtain their medication from legitimate providers.

Through the use of biometrics, Bio-Tech Medical Software, Inc. is taking an innovative approach to combat the ever growing problem of prescription drug abuse as well as using biometrics to prevent identity fraud which is currently used to circumvent prescription monitoring programs in 32 other states. These diverted drugs account for the statistical approximate average of seven drug related deaths that occur in Florida daily. Patients will not only benefit from faster access to their legitimate medications, but doctors and pharmacists will also benefit from greater trust ensuring their prescriptions are not stolen, diverted, or otherwise used for drug abuse. This system will help to save lives and dollars through biometrics making it the most advanced technology being offered exclusively to the State of Florida.

By utilizing the University Incubator and the expertise of the university itself, Bio-Tech Medical Software, Inc. increases its leverage to accelerate the program's development and the company's growth. This is another perfect example of the innovative dynamic thinking of the company's ability to assist the public in efforts to fight against drug diversion.

For more information on Bio-Tech Medical Software, Inc. and its biometric medical software program, please e-maillarry.hooper@bioscriptrx.com or please call 800-797-4711.

Contacts

Bio-Tech Medical Software, Inc.,
Dr. Larry Hooper, 800-797-4711, ext#101

KIKA Medical Celebrates Banner 2008: Expands US-Based EDC Market

BOSTON, MA and PARIS - KIKA Medical, the leading provider of advanced EDC solutions for clinical trials, celebrated a successful 2008 and is poised for continued strong growth this year.

Among KIKA's significant milestones last year was the August appointment of CEO Linda Beneze, a respected eClinical professional with a distinguished 25-year career. Previously Ms. Beneze was Vice President of Sales and Client Services at PHT Corporation. She also held executive roles at Phase Forward and Bard Vascular Systems.

Ms. Beneze said, "We're on track with an ambitious plan to increase our customer base and revenues on a global basis as more and more pharmaceutical and medical device companies choose KIKA's clinical asset management for reliable, flexible, accurate trials." KIKA 2008 highlights included:

18 New Trials -- In its first full year with a base of operations in the U.S., KIKA signed 18 new trials from new and existing clients. Trials included cardiovascular, oncology, and orthopedics.

New Version of KIKA Clinical Asset Management Platform -- The newest version of Clinical Asset Management solution is KIKA's exclusive 3-part approach to electronic clinical trial solutions: breakthrough Web-based technology, professional support, and established IT infrastructure. KIKA's platform includes Veracity(TM), a Web-based software platform that is customized to meet study needs precisely -- from the intuitive user interface that makes EDC truly flexible, reliable and user-friendly. The result is flexibility and customization, end-user empowerment, and responsiveness and support -- all to protect clinical assets and help bring much-needed medical solutions to market faster.

10 Years of Reliable Data Hosting -- KIKA marked its 10th year of hosting sponsors' mission-critical clinical data with less than two hours of downtime during the entire period. KIKA's system has a unique proxy store which automatically replicates data on the fly as it is collected and sends it to a mirror site that can take over in the event of a crash or natural disaster.

U.S. Executive Team in Place -- In addition to CEO Linda Beneze, KIKA named senior industry executive Kristine Klinger as Vice President of Professional Services; and added five new Directors of Business Development in the U.S. and Europe.

Strategic Partnerships -- KIKA signed new trials through partner companies including Genae, a CRO specializing in cardiovascular and endovascular therapies and medical devices; and continued to offer EDC solutions through academic CRO Cardialysis, a provider of imaging core laboratory techniques, clinical event adjudication services and services for studies in the cardiac area.

Spreading the Clinical Asset Management Message -- KIKA representatives participated in conferences around the globe to discuss important trends and advances in clinical asset management and advanced EDC. Venues included the Clinical Trial Conference; the annual DIA Conference & Exhibition; the Bio-IT World 2008 Annual Meeting; the DIA Annual Meeting; the Transcatheter Cardiovascular Conference; and the EuroPCR.

China Bio-Immunity Corporation - Rabies Vaccine Recall

China Bio-Immunity Corporation - Rabies Vaccine Recall

DALIAN, China, March 5 /PRNewswire-FirstCall/ -- China Bio-Immunity Corporation (OTC Bulletin Board: CHHB) (China Bio-Immunity" or "the Company"), a China-based company that develops, produces, manufactures and markets proprietary vaccine-based prophylactics and therapeutics exclusively within China through it wholly-owned subsidiary, Dalian Jingang-Andi Bio-products Co. Ltd (Dalian JGAD), today announced an update regarding the nationwide recall of its rabies vaccines. The National Institute for the Control of Pharmaceutical and Biological Products has reported that the Company's flawed rabies vaccines contained nucleic acid, which as a prescription drug has been legally produced by more than twenty manufacturers in China and widely used in the Chinese market. However, it has not yet been approved as an ingredient to be added in human rabies vaccine in China. Although tests on animals demonstrated that the nucleic acid did enhance the effectiveness of the human rabies vaccine, it had to undergo clinical trials before it could be used as an adjuvant in human rabies vaccines. Dalian JGAD was found falling afoul of such regulatory rules. Among 360,200 doses of the flawed rabies vaccines in China, a total of 323,200 have been recovered by the manufacturer, Dalian JGAD. The rest of the rabies vaccines were not used and had been held for recall. To date, there has been no report of vaccine related illness received by Chinese National Center for Adverse Drug Reaction Monitoring. Furthermore, the China State Food and Drug Administration ("SFDA") has confiscated all the flawed products and profits from the sales of the flawed rabies vaccines. The SFDA will also assess a punitive fine of 145 Million Chinese Yuan. Dalian JGAD has been suspended from production and sales of vaccines since the recall. The production permit of Dalian JGAD was also revoked. Additionally, the key officers involved have been forbidden from engaging in any production activities within the pharmaceutical industry for a period of ten years. Two senior executives and one purchasing agent of Dalian JGAD have been detained by local authorities. Safe Harbor Statement The Statements contained in this press release are being made on the basis of the Company's review of the situation to date. Furthermore, the information contained herein may change as the governmental investigation is ongoing. Additionally, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward looking statements in this press release.